NDA 219947 · Arrowhead
Redemplo
Plozasiran Sodium · Subcutaneous · APOC-III-directed RNA Interaction; Small Interfering RNA
NovelBreakthrough therapyOrphanCDER novel approval, Nov 18, 2025: To reduce triglycerides in adults with familial chylomicronemia syndrome
Last checked: Nov 19, 2026Latest source record: Nov 18, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Nov 18, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
8
7 Phase 3, 1 recruiting
FAERS reports
104
13 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 25, 2026.
REDEMPLO is indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). REDEMPLO is an apolipoprotein C-III ( apoC-III )-directed small interfering ribonucleic acid (siRNA) indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). ( 1 )
Mechanism: Plozasiran is a siRNA conjugated with GalNAc that degrades the apoC-III mRNA through the RNA interference mechanism resulting in reduced levels of hepatic and serum apoC-III protein. Reduction of apoC- III protein leads to increased clearance of serum triglycerides.
Therapeutic areas: Cardiovascular and metabolic · Rare and genetic disease
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 18, 2025 Original approval · Type 1 - New Molecular Entity NovelBreakthrough therapyOrphanLabelLetterReview
1 products under this application
- REDEMPLO · PLOZASIRAN SODIUM EQ 25MG BASE/0.5ML (EQ 25MG BASE/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Plozasiran" as an intervention, any sponsor and status, largest first.
- Phase 3 Study of Plozasiran in Adults With HypertriglyceridemiaPivotal-lookingCompleted
Arrowhead PharmaceuticalsIndustry
NCT06347133 · 1,456 participants · Start May 21, 2024 · Primary completion Jun 1, 2026
Drug: Plozasiran Injection; Placebo · For: Hypertriglyceridemia
Sites: Birmingham, Alabama; Mobile, Alabama; Beverly Hills, California · 235 sites in all
- Long-Term Safety and Efficacy of Plozasiran in Adults With HypertriglyceridemiaPivotal-lookingActive, not recruiting
Arrowhead PharmaceuticalsIndustry
NCT06822790 · 710 participants · Start Apr 9, 2025 · Primary completion Jul 2028
Drug: Plozasiran Injection · For: Hypertriglyceridemia
Sites: Bakersfield, California; Beverly Hills, California; Canoga Park, California · 253 sites in all
- Study of Plozasiran (ARO-APOC3) in Adults With Severe HypertriglyceridemiaPivotal-lookingCompleted
Arrowhead PharmaceuticalsIndustry
NCT06347003 · 446 participants · Start Jul 22, 2024 · Primary completion Jun 12, 2026
Drug: Plozasiran Injection; Placebo · For: Severe Hypertriglyceridemia
Sites: Garden Grove, California; Lake Forest, California; Montclair, California · 196 sites in all
- Study of Plozasiran (ARO-APOC3) in Adults With Mixed DyslipidemiaPivotal-lookingCompleted
Arrowhead PharmaceuticalsIndustry
NCT04998201 · 353 participants · Start Sep 28, 2021 · Primary completion Feb 10, 2023
Drug: ARO-APOC3; Placebo · For: Mixed Dyslipidemia
Sites: Beverly Hills, California; Northridge, California; Boca Raton, Florida · 30 sites in all
- Study of Plozasiran in Adults With Severe HypertriglyceridemiaPivotal-lookingCompleted
Arrowhead PharmaceuticalsIndustry
NCT06347016 · 311 participants · Start Jul 23, 2024 · Primary completion Jun 17, 2026
Drug: Plozasiran Injection; Placebo · For: Severe Hypertriglyceridemia
Sites: Birmingham, Alabama; Mobile, Alabama; Beverly Hills, California · 149 sites in all
- Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute PancreatitisPivotal-lookingRecruiting
Arrowhead PharmaceuticalsIndustry
NCT06880770 · 288 participants (planned) · Start Apr 24, 2025 · Primary completion Mar 2029
Drug: Plozasiran; Placebo · For: Severe Hypertriglyceridemia
Sites: Los Angeles, California; Santa Clarita, California; New Haven, Connecticut · 140 sites in all
- Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)Pivotal-lookingCompleted
Arrowhead PharmaceuticalsIndustry
NCT05089084 · 75 participants · Start Dec 14, 2021 · Primary completion Apr 29, 2024
Drug: Plozasiran; Placebo · For: Familial Chylomicronemia
Sites: Boca Raton, Florida; Suwanee, Georgia; Indianapolis, Indiana · 58 sites in all
- A Phase 3 Study of ARO-APOC3 / VSA001 / SAR449124 (Plozasiran) in Chinese Adults With Familial Chylomicronemia SyndromePivotal-lookingCompleted
Visirna Therapeutics HK LimitedIndustry
NCT05902598 · 37 participants · Start Jul 10, 2023 · Primary completion Nov 26, 2024
Drug: Plozasiran; Placebon · For: Familial Chylomicronemia Syndrome
Sites: Shanghai, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- headache21
- nausea20
- blood glucose increased15
- injection site pain7
- fatigue5
- feeling abnormal5
- hyperglycaemia5
- blood triglycerides increased4
- dizziness4
- drug ineffective4
- dyspnoea4
- abdominal discomfort3
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2026 | 104 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk.
Watts GF, Rosenson RS, Hegele RA, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia: The SHASTA-2 Randomized Clinical Trial.
Gaudet D, Pall D, Watts GF, et al. · JAMA Cardiol 2024 · Randomized Controlled Trial, Clinical Trial, Phase II
- Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia.
Ballantyne CM, Vasas S, Azizad M, et al. · N Engl J Med 2024 · Randomized Controlled Trial, Clinical Trial, Phase II
- Novel agents for treating severe hypertriglyceridemia.
Wierzbicki AS · Med 2024 · Randomized Controlled Trial
- Safety, pharmacokinetics and pharmacodynamics of Plozasiran in Chinese healthy volunteers.
Wang F, You D, Niu X, et al. · Cardiovasc Diabetol 2025 · Randomized Controlled Trial, Clinical Trial, Phase I
- Safety and Efficacy of the Novel RNA Interference Therapies for Hypertriglyceridemia and Mixed Hyperlipidemia Management: A Systematic Review and Meta-analysis.
Kamrul-Hasan ABM, Dutta D, Nagendra L, et al. · Endocr Pract 2024 · Systematic Review, Meta-Analysis
Sponsor: Arrowhead
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.